NH Therapeutics, a biopharmaceutical company that focuses on developing drugs and therapies for effective treatment of rare neuroendocrine disorders, recently announced that European Medicine Agency has awarded its leading drug candidate...
Read More
ONCURIOUS NV receives orphan drug status for TB-403 for Medulloblastoma
Release Date: 17 February 2017
Oncurious NV, an oncology development company dedicated to develop innovative orphan drugs for the treatment of pediatric tumors, has received orphan drug designation for its novel product, TB-403 from European Medicine Agency (EMA) for the treatment of patients with ...
Read More
EC grants orphan drug designation to Therabron Therapeutic’s CG367
Release Date: 16 February 2017
Therabron Therapeutics has recently announced that European Union has awarded its leading drug candidate, CG367 with orphan drug designation for the treatment of Bronchiolitis Obliterans Syndrome. Previously CG367 has been granted orphan...
Read More
Arthritis in Children gets orphan drug by FDA
Release Date: 15 February 2017
US Food and Drug Administration has granted orphan drug designation to an oral liquid suspension of celecoxib for the treatment of children suffering from pediatric juvenile idiopathic arthritis. The liquid suspension is developed and fo...
Read More
Abeona receives orphan drug designation for ABO-101 to treat Sanfilippo Syndrome Type- B
Release Date: 14 February 2017
Abeona therapeutics, a clinical stage bio-pharmaceutical company dedicated to develop gene therapies for life threatening diseases, has recently announced that its novel gene therapy candidate, ABO-101 has been awarded with orphan drug s...
Read More
Idogen receives orphan drug status for Hemophilia A
Release Date: 13 February 2017
European Commission has granted orphan drug designation to Idogen for the treatment of patients with Hemophilia A. The European Commission grants orphan drug designation status to provide incentives to develop medicinal products to treat...
Read More
FDA grants orphan drug designation to sickle cell treatment
Release Date: 12 February 2017
Imara therapeutics, a leading biopharmaceutical announced that US Food and Drug Administration have granted orphan drug designation to its novel drug, IMR-657 to treat patients with Sickle cell disease. Presently, IMR-657 is stepping tow...
Read More
FDA grants orphan drug designation to lysogene’s LYSGM101 for GM1 Gangliosidosis
Release Date: 11 February 2017
US Food and Drug Association has designated LYGSM101 as orphan drug, developed by Lysogene, a clinical stage biotechnology company focused on developing gene therapy for rare central nervous system diseases, for the treatment of GM1 Gang...
Read More
Angiosarcoma gets orphan drug as Propranolol by EC
Release Date: 10 February 2017
European Commission has granted Orphan Drug Designation to Propranolol for the treatment of Angiosarcoma, a lethal form of soft tissue sarcoma. Propranolo...
Read More
EMA grants orphans drug status to Therabron Therapeutics’ CG367
Release Date: 09 February 2017
European Medicine Agency has awarded Therabron Therapeutics, a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care; with Orphan drug Designation for its leading product candidate, CG367, for the...
Read More
Viralym-C receives orphan status to treat CMV
Release Date: 08 February 2017
Viracyte, a biopharmaceutical agency focused on developing immunotherapies for death causing infections, has recently announced that US Food and Drug Administration has granted Orphan Drug Designation to Viralym-C, the company’s le...
Read More
CIRARA by Remedy Pharmaceuticals receives Orphan Drug Status
Release Date: 07 February 2017
US Food and Drug Administration (FDA) has announced orphan drug designation for CIRARA, an investigational drug developed by Remedy Pharmaceuticals, a privately owned pharmaceutical company dedicated to develop lifesaving hospital based ...
Read More
ProMetic's PBI-4050 recieves orphan drug status for Alström Syndrome: EC
Release Date: 07 February 2017
European Commission has granted orphan drug designation for the ProMetic Life Sciences Inc.’ orally active lead drug candidate, PBI-4050 for the treatment of Alstrandouml;m Syndrome ("AS"). It is a rare inherited autosomal re...
Read More
GenSight Biologics announces orphan drug status for GS030 for Retinitis Pigmentosa
Release Date: 05 February 2017
GenSight Biologics, a biopharma company focused on developing innovative gene therapy for neurodegenerative retinal diseases and diseas for central nervous system, has received Orphan Drug Designation by US Food and Drug Administration (...
Read More
EC Orphan Drug Designation for Cabiralizumab (FPA008) for PVNS
Release Date: 04 February 2017
Five Prime Therapeutics Inc. has announced orphan drug designation by European Commission for its novel therapy, Cabiralizumab (FPA008) for the treatment of tenosynovial giant cell tumour, localised and diffuse type, also known as Pigmen...
Read More
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |
